Biden administration’s limit on drug industry middlemen backfires, pharmacists say

The Biden administration’s first major step toward imposing limits on the pharmacy benefit managers who act as the drug industry’s price negotiators is backfiring, pharmacists say.

Keytruda combination treatment for NSCLC falls short in Phase III – Pharmaceutical Technology

Share this article The Keytruda / Lynparza treatment is being studied as a first-line treatment for certain types of patients with NSCLC. Credits: Sonis Photography/Shutterstock.com

March 21, 2024

Nyxoah Raises $27 Million through its At-the-Market Offering – Biotech Investments

EQS-News: Nyxoah SA. / Key word(s): Financing Nyxoah Raises $27 Million through its At-the-Market Offering 08.10.2024 / 14:00 CET/CEST The issuer is solely responsible for

October 9, 2024

Stronger at 60 vs 50 Years Old: Chris Cornell’s Health Journey – BioHackers Lab

On this episode of Biohackers Lab I talk to Chris Cornell. We discuss Chris’s incredible journey of transformation. Despite being in poor shape at 51,

January 30, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.